Announcements

Announcements
 
 
BMGF – Gates Foundation  [to 22 Dec 2018]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 22 Dec 2018]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 22 Dec 2018]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 22 Dec 2018]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 22 Dec 2018]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
21 December 2018
Report on the Lisbon meeting for the next EDCTP programme published
EDCTP organised a high-level meeting on the character, scope and shape of its next programme in Lisbon, Portugal, on 17 September 2018. Approximately 100 participants representing EDCTP member countries and strategic partners in global health participated to discuss their involvement…
 
 
Emory Vaccine Center    [to 22 Dec 2018]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 22 Dec 2018]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 
 
European Vaccine Initiative  [to 22 Dec 2018]
http://www.euvaccine.eu/news-events
No new digest content identified.
 
 
FDA [to 22 Dec 2018]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
 
 
Fondation Merieux  [to 22 Dec 2018]
http://www.fondation-merieux.org/
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)

Event
Alain Mérieux receives the prestigious Chinese Reform Friendship Award
December 18, 2018 – Beijing (China)
Alain Mérieux received the Reform Friendship Award at a conference celebrating the 40th anniversary of China’s Reform and Opening Up on December 18, 2018. The event took place at the Great Hall of the People in Beijing, in the presence of President Xi Jinping.

Gavi [to 22 Dec 2018]
https://www.gavi.org/
No new digest content identified.

GHIT Fund   [to 22 Dec 2018]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 22 Dec 2018]
https://www.theglobalfund.org/en/news/

Feature Story
2018: A Look Back
18 December 2018
As the calendar page turns, we look back on some of the stories and moments that shaped 2018. Celebrating the 27 million lives saved. Honoring those we have lost. Amplifying the voices of people and communities most affected by the epidemics. Welcoming new leadership and partnerships. And accelerating investment and innovation to achieve a future free of the burden of HIV, tuberculosis, and malaria

 

Hilleman Laboratories   [to 22 Dec 2018]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 22 Dec 2018]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.
 
 
IAVI  [to 22 Dec 2018]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 22 Dec 2018]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 22 Dec 2018]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.
 
 
JEE Alliance  [to 22 Dec 2018]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 22 Dec 2018]
http://www.msf.org/
Selected News; Project Updates, Reports

Niger
Preventing future outbreaks in a cholera hotspot
Project Update 17 Dec 2018
Since early July, Niger has been battling its worst cholera outbreak in years.
As the disease ebbs, Médecins Sans Frontières (MSF) and local health authorities shift their focus to preventing future outbreaks in the southern region of Maradi, most affected by the current epidemic and known as a hotspot for cholera along the border of Niger and Nigeria.
These efforts include vaccinating over 145,000 people with an easy-to-administer oral vaccine in three of Maradi’s health zones: Tchadoua, Aguié and Gazaoua.
MSF has provided local health authorities with logistical and technical support. Epicentre, a research unit created by MSF to provide epidemiological expertise that underpins operations, is supporting the intervention with a post-vaccination survey…
 
 
NIH  [to 22 Dec 2018]
http://www.nih.gov/news-events/news-releases
No new digest content identified.
 
 
PATH  [to 22 Dec 2018]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 22 Dec 2018]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 22 Dec 2018]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.
 
 
UNICEF  [to 22 Dec 2018]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
Child given world’s first drone-delivered vaccine in Vanuatu – UNICEF
With 1 in 5 children in the remote Pacific island nation not fully immunized, UNICEF partners with the Government on first-ever commercial contract to deliver vaccines by drone
18/12/2018
[See Milestones above for detail]
 
 
Vaccine Confidence Project  [to 22 Dec 2018]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 22 Dec 2018]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 22 Dec 2018]
https://wellcome.ac.uk/news
19 December 2018
Why we need a globally coordinated approach to preparing for epidemics
At $60 billion a year, not preparing for epidemics costs far more than putting the systems in place to prevent infectious diseases from spreading around the globe. Here’s why.

News | 18 December 2018
Value of Wellcome’s investments passes £25 billion
The value of our investments portfolio grew to almost £25.9 billion by 30 September 2018, strengthening our ambition to spend more than £5 billion over five years on our charitable activities.

17 December 2018
Research should be at the heart of an epidemic response
If we put research at the heart of epidemic response, it’s a double win – helping fight outbreaks that are underway and protecting us in the future.

 
The Wistar Institute   [to 22 Dec 2018]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 22 Dec 2018]
http://www.oie.int/en/for-the-media/press-releases/2018/
No new digest content identified.
 
 
::::::
 
BIO    [to 22 Dec 2018]
https://www.bio.org/insights/press-release
Dec 20 2018
BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Washington, DC (December 20, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement applauding passage today by the House of Representatives of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 7328). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 22 Dec 2018]
http://www.dcvmn.org/
No new digest content identified.
 
 
IFPMA   [to 22 Dec 2018]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.
 
 
PhRMA    [to 22 Dec 2018]
http://www.phrma.org/press-room
No new digest content identified.
 
 
Industry Watch    [to 22 Dec 2018]
:: Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
Wednesday, December 12, 2018 10:30 am EST
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiologic products for Brazil today announced a collaboration agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan and Merck have licensed certain rights from National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), for the development of live attenuated tetravalent vaccines (LATV). Instituto Butantan’s dengue vaccine candidate, TV003, is currently being evaluated in a large Phase 3 study in Brazil.

“By sharing data from our ongoing vaccine development programs, Instituto Butantan and Merck are better positioned to achieve our goal of reducing the significant human and economic toll of dengue virus in Brazil and around the world,” said Dr. Dimas Covas, director, Instituto Butantan. “We look forward to collaborating with Merck, an established global leader in vaccine development.”

Under the agreement, Merck and Instituto Butantan have agreed to collaborate to share clinical data and other learnings from their respective dengue vaccine development programs, both derived from licensed materials from the NIAID. Instituto Butantan will receive a $26 million upfront payment from Merck and is eligible to receive up to $75 million for the achievement of certain milestones related to the development and commercialization of Merck’s investigational vaccine as well as potential royalties on sales. Instituto Butantan will retain responsibility for the manufacturing and commercialization of their investigational vaccine, TV003, in Brazil.

“This agreement recognizes the tremendous progress that scientists and clinicians at the Instituto Butantan have made in developing their investigational dengue virus vaccine,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “Through our new collaboration, we together have made a commitment to help protect people around the world who are at risk of developing dengue virus disease.”

The agreement builds upon a productive long-term collaboration between MSD Brazil and Instituto Butantan, initiated in 2012, for human papillomavirus (HPV) and Hepatitis-A vaccine products.